These results support the further investigation of delivery of MEK1 to macrophages as a form of cancer therapy while also developing better targeting of MEK1 inhibitors to specifically inhibit MEK1 in tumours while sparing MEK1 activity in immune cells such as macrophages. Here, MAP2K1 is linked to neoplasm.